Health
Peru suspends Sinopharm COVID-19 vaccine trial after ‘adverse event’ – Sydney Morning Herald
Peru’s health ministry said the event is “under investigation to determine if it is related to the vaccine or if there is another explanation”.
German Malaga, chief researcher at the local Cayetano Heredia University, which is involved with the study, said one volunteer had experienced decreased strength in his legs among other symptoms, and the condition could be related to Guillain-Barré syndrome.
The Brazilian government has meanwhile unveiled its long-awaited national vaccination plan against COVID-19, with an initial goal of vaccinating 51 million people, or about a quarter of the population, in the first half of 2021.
In a document…
-
Noosa News20 hours agoForensic teams, dogs descend on scene of alleged murder
-
General20 hours agoDrone pilot course in doubt as Queensland reviews school-based training
-
Business24 hours agoSuper Retail shares lifting on big leadership news
-
Business18 hours ago3 excellent ASX ETFs for Aussies over 60